Trial Profile

A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belumosudil (Primary)
Indications Diffuse scleroderma
Focus Therapeutic Use
Acronyms dcSSC
Sponsors Kadmon Holdings; Sanofi

Most Recent Events

11 Apr 2025 Results assessing AI-derived fibrosis scores from skin biopsies relate to both histologic features and clinical skin thickness (mRSS) in systemic sclerosis patients treated with belumosudil were published in the Arthritis Research and Therapy.
20 Mar 2023 Status changed from completed to discontinued.
05 Jan 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com